About this Journal Submit a Manuscript Table of Contents
ISRN Oncology
Volume 2013 (2013), Article ID 863909, 5 pages
http://dx.doi.org/10.1155/2013/863909
Clinical Study

Infusion Rate Escalation Study of Rituximab in Patients with CD20+ B-Cell Lymphomas: A Single Institution Analysis in Japan

1Department of Hematology, Cancer Institute Hospital, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan
2Division of Pathology, The Cancer Institute, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan
3Pathology Project for Molecular Targets, The Cancer Institute, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan
4Division of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan

Received 11 February 2013; Accepted 28 February 2013

Academic Editors: W. Kildal and Y.-Y. Liu

Copyright © 2013 Masahiro Yokoyama et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. McLaughlin, A. J. Grillo-López, B. K. Link et al., “Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program,” Journal of Clinical Oncology, vol. 16, no. 8, pp. 2825–2833, 1998. View at Scopus
  2. B. Coiffier, E. Lepage, J. Brière et al., “Chop chemotherapy plus rituximab compared with chop alone in elderly patients with diffuse large-B-cell lymphoma,” The New England Journal of Medicine, vol. 346, no. 4, pp. 235–242, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Marcus, K. Imrie, A. Belch et al., “CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma,” Blood, vol. 105, no. 4, pp. 1417–1423, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. M. H. J. van Oers, R. Klasa, R. E. Marcus et al., “Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial,” Blood, vol. 108, no. 10, pp. 3295–3301, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. J. D. Hainsworth, S. Litchy, D. W. Shaffer, L. Van Lackey, M. Grimaldi, and F. A. Greco, “Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma—a randomized phase II trial of the Minnie Pearl Cancer Research Network,” Journal of Clinical Oncology, vol. 23, no. 6, pp. 1088–1095, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Salar, D. Casao, M. Cervera et al., “Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-yr experience in a single institution,” European Journal of Haematology, vol. 77, no. 4, pp. 338–340, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. L. H. Sehn, J. Donaldson, A. Filewich et al., “Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting,” Blood, vol. 109, no. 10, pp. 4171–4173, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Siano, E. Lerch, L. Negretti et al., “A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function,” Clinical Cancer Research, vol. 14, no. 23, pp. 7935–7939, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Tuthill, T. Crook, T. Corbet, J. King, and A. Webb, “Rapid infusion of rituximab over 60 min,” European Journal of Haematology, vol. 82, no. 4, pp. 322–325, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Provencio, A. Sanchez, C. Maximiano, B. Cantos, M. Méndez, and F. Bonilla, “A prospective study of left ventricle function after treatment with rapid-infusion Rituximab in patients with non-Hodgkin lymphoma,” Leukemia & Lymphoma, vol. 50, no. 10, pp. 1642–1646, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Chiang, A. Chan, V. Shih, S. W. Hee, M. Tao, and S. T. Lim, “A prospective study to evaluate the feasibility and economic benefits of rapid infusion rituximab at an Asian cancer center,” International Journal of Hematology, vol. 91, no. 5, pp. 826–830, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. S. H. Swerdlow, E. Campo, and N. L. Harris, Eds., World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, 2008.